Rhinosinusitis Market

 Market Overview:

The 7 major rhinosinusitis markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.64% during 2024-2034.

The rhinosinusitis market has been comprehensively analyzed in IMARC's new report titled "Rhinosinusitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rhinosinusitis refers to a medical condition in which the paranasal sinuses and the mucous membranes around the nasal passages become infected and inflamed. The disease is characterized by obstruction and/or nasal congestion or a runny nose with discharge that may drain at the back or front of the nose. Depending on its duration, the illness is classified as acute or chronic rhinosinusitis. The common symptoms of this ailment include difficulty breathing, swelling and pain throughout the face, stuffiness, headache, itchy nose, fatigue, discolored or cloudy nasal discharge, decreased sense of smell, persistent cough, etc. Additionally, individuals suffering from rhinosinusitis may experience swelling around the eyes, pus, phlegm, fever, sore throat, etc. The diagnosis of this disease is based on a review of the patient's symptoms and a physical examination with a nasal endoscopy. The healthcare professional may also perform diagnostic procedures, such as a computed tomography (CT) scan that combines X-rays to provide a detailed 3-D image of the affected areas.

The increasing incidences of allergies and bacterial or viral infections, which can irritate the nasal passage, leading to blockages and fluid accumulation, are primarily driving the rhinosinusitis market. In addition to this, the rising prevalence of various risk factors, including a weakened immune system, smoking, structural abnormalities in the nasal cavity, certain comorbid medical conditions, etc., is also bolstering the market growth. Furthermore, the widespread adoption of over-the-counter pain relievers, such as acetaminophen, ibuprofen, aspirin, etc., to help reduce pain and fever associated with the disease is acting as another significant growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to launch novel diagnostic tools for early diagnosis of rhinosinusitis and treatment monitoring in patients. This, in turn, is also creating a positive outlook for the market. Moreover, the inflating utilization of topical intranasal therapy, since it can reduce inflammation and correct mucociliary dysfunction, is further propelling the market growth. Besides this, the emerging popularity of allergy shots (immunotherapy), which limit the body's reaction to specific allergens and help treat the symptoms, is expected to drive the rhinosinusitis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the rhinosinusitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for rhinosinusitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rhinosinusitis market in any manner.

Recent Developments:

• In March 2024, Optinose reported that the US Food and Drug Administration (FDA) had approved XHANCE (fluticasone propionate) nasal spray for the management of chronic rhinosinusitis without nasal polyps in patients aged 18 and above.
• In February 2024, SaNOtize Research & Development Corp. announced that it had initiated a Phase 2 safety and efficacy trial of a new Nitric Oxide Nasal Spray (NONS) for the treatment of recurrent acute rhinosinusitis. The trial will focus on treating patients as soon as a sinusitis episode begins and will assess the effectiveness of NONS treatment in reducing the time to recovery from the sinusitis episode with symptom resolution.

Key Highlights:

• Epidemiologic research shows that the prevalence of chronic rhinosinusitis ranges from 5% to 12%.
• Chronic rhinosinusitis affects one out of every eight people in India or approximately 5-15% of the urban population.
• Its estimated incidence is 12.3% in the United States and 10.9% in Europe.
• Rhinosinusitis is more common in adults (age 18-64) than in children, mostly due to more developed sinus cavities.
• According to epidemiological research, women have approximately double the rate of chronic rhinosinusitis as males.

Drugs:

Dupixent is available in a 300 mg pre-filled syringe for individuals with chronic rhinosinusitis with nasal polyposis. It is administered as a subcutaneous injection every other week at several injection sites. Dupixent is intended for use under the supervision of a healthcare professional and can be administered in a clinic or at home by self-administration after receiving instruction from a healthcare expert.

Tezepelumab is an investigational, possibly first-in-class human monoclonal antibody being developed by AstraZeneca and Amgen. It targets the airway epithelium, which is the first point of contact for pollutants, viruses, allergens, and other environmental insults and is the main cause of inflammation. Tezepelumab specifically targets and inhibits thymic stromal lymphopoietin (TSLP), a critical epithelial cytokine that sits at the top of numerous inflammatory cascades and triggers an overreactive immune response to allergic, eosinophilic, and other kinds of airway inflammation.

LYR-210 is a bioabsorbable nasal mesh that is administered during a quick in-office procedure.  LYR-210 is designed to administer up to six months of continuous, proven anti-inflammatory medication, mometasone furoate, into the sinonasal passageways to treat chronic rhinosinusitis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the rhinosinusitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the rhinosinusitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current rhinosinusitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the rhinosinusitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the rhinosinusitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the rhinosinusitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of rhinosinusitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rhinosinusitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rhinosinusitis by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rhinosinusitis by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with rhinosinusitis across the seven major markets?
• What is the size of the rhinosinusitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of rhinosinusitis?
• What will be the growth rate of patients across the seven major markets?
   

Rhinosinusitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for rhinosinusitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rhinosinusitis market?
• What are the key regulatory events related to the rhinosinusitis market?
• What is the structure of clinical trial landscape by status related to the rhinosinusitis market?
• What is the structure of clinical trial landscape by phase related to the rhinosinusitis market?
• What is the structure of clinical trial landscape by route of administration related to the rhinosinusitis market?